Abstract | AIMS:
Diffuse large B-cell lymphoma (DLBCL) is characterised by marked clinical and biological heterogeneity, attributable to the tumour cells and their microenvironment. METHODS: In this study, we investigated circulating subsets of blood lymphocytes and monocytes and their relationship with T cells in the tumour microenvironment (TME) in chemoresistant and chemosensitive patients with DLBCL. RESULTS: The study showed that (1) absolute lymphocyte count (ALC) and CD3+ and CD4+ cells were reduced in chemoresistant patients compared with chemosensitive patients; (2) lymphocyte:monocyte ratio (LMR) showed a positive correlation with peripheral blood CD3+ and CD4+ cells; (3) ALC, LMR, peripheral blood CD3+ and CD4+ cells showed a positive correlation with T cells in the TME. CONCLUSIONS: Overall, these data suggest that DLBCL with high TME T cells display a pre-existing antitumour immune response. In the rituximab-containing regimen, TME T cells are stimulated further to participate in the immune response against lymphoma cells. In contrast, DLBCL lymphomas with low T-cell infiltration reflect the absence of a pre-existing antitumour immunity and have a lower likelihood of obtaining an optimal response to therapy.
|
Authors | Filomena Emanuela Laddaga, Giuseppe Ingravallo, Anna Mestice, Roberto Tamma, Tommasina Perrone, Eugenio Maiorano, Domenico Ribatti, Giorgina Specchia, Francesco Gaudio |
Journal | Journal of clinical pathology
(J Clin Pathol)
Vol. 75
Issue 7
Pg. 493-497
(Jul 2022)
ISSN: 1472-4146 [Electronic] England |
PMID | 34011621
(Publication Type: Journal Article)
|
Copyright | © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. |
Topics |
- Humans
- Lymphocyte Count
- Lymphocytes
(pathology)
- Lymphoma, Large B-Cell, Diffuse
(pathology)
- Monocytes
(pathology)
- Prognosis
- Tumor Microenvironment
|